Ondine Biomedical to Announce Interim Financial Results

Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.

Ondine Biomedical Inc. announced it will release its unaudited interim financial results for the period ending 30 June 2025 on 26 September 2025. A live presentation of the results will be conducted by Dr. Nicolas Loebel and Alan Thomas, which is open to all existing and potential shareholders. This announcement provides an opportunity for stakeholders to gain insights into the company’s financial performance and strategic direction, potentially impacting investor confidence and market positioning.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, which are in various stages of development. Its nasal photodisinfection system, Steriwave®, is CE-marked in Europe and approved in Canada, Australia, Mexico, and other countries. In the U.S., it has received Qualified Infectious Disease Product designation and Fast Track status by the FDA and is undergoing clinical trials.

Average Trading Volume: 388,395

Technical Sentiment Signal: Buy

Current Market Cap: £77.76M

See more insights into OBI stock on TipRanks’ Stock Analysis page.